PODXL and neoplasm: A later finding is that tumor-cell-specific PODXL expression is associated with a more aggressive phenotype and adverse outcome in several cancer types, for example, in breast [6], prostate [8], ovarian [9], colorectal [10–12], urothelial bladder [13], pancreatic [14], and periampullary cancer [15].